Literature DB >> 25117747

Multiparametric magnetic resonance imaging for the differentiation of low and high grade clear cell renal carcinoma.

F Cornelis1, E Tricaud, A S Lasserre, F Petitpierre, J C Bernhard, Y Le Bras, M Yacoub, M Bouzgarrou, A Ravaud, N Grenier.   

Abstract

PURPOSE: To retrospectively evaluate the ability of magnetic resonance (MR) imaging to differentiate low from high Fuhrman grade renal cell carcinoma (RCC).
MATERIALS AND METHODS: MR images from 80 consecutive pathologically proven RCC (57 clear cell, 16 papillary and 7 chromophobe) were evaluated. Double-echo chemical shift, dynamic contrast-enhanced T1- and T2-weighted images and apparent diffusion coefficient (ADC) maps were reviewed independently. Signal intensity index (SII), tumour-to-spleen SI ratio (TSR), ADC ratio, wash-in (WiI) and wash-out indices (WoI) between different phases were calculated and compared to pathological grade and size. The Fuhrman scoring system was used. Low grade (score ≤ 2) and high grade (score ≥ 3) tumours were compared using univariate and multivariate analyses.
RESULTS: No associations between grade and imaging factors were found for papillary and chromophobe RCCs. For clear cell RCCs, there was a significant association between the grade and parenchymal WiI (WiI2) (P = 0.02) or ADCr (P = 0.03). A significant association between tumour grade and size (P = 0.01), WiI2 (P = 0.02) and ADCr (P = 0.05) remained in multivariate analysis.
CONCLUSIONS: Multiparametric MRI can be used to accurately differentiate low Fuhrman grade clear cell RCC from high grade. High Fuhrman grade (≥ 3) RCCs were larger, had lower parenchymal wash-in indices and lower ADC ratios than low grade. KEY POINTS: • Fuhrman grade of clear cell RCC can be differentiated with multiparametric MR imaging. • Fuhrman grade significantly differed for size, parenchymal wash-in index and ADC ratio. • No significant associations were found for papillary and chromophobe renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25117747     DOI: 10.1007/s00330-014-3380-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  45 in total

1.  Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy.

Authors:  Michael J Leveridge; Antonio Finelli; John R Kachura; Andrew Evans; Hannah Chung; Daniel A Shiff; Kimberly Fernandes; Michael A S Jewett
Journal:  Eur Urol       Date:  2011-06-24       Impact factor: 20.096

2.  Accuracy of on-bench biopsies in the evaluation of the histological subtype, grade, and necrosis of renal tumours.

Authors:  Vincenzo Ficarra; Matteo Brunelli; Giacomo Novara; Carolina D'Elia; Diego Segala; Marina Gardiman; Walter Artibani; Guido Martignoni
Journal:  Pathology       Date:  2011-02       Impact factor: 5.306

Review 3.  The current role of percutaneous biopsy in the evaluation of renal masses.

Authors:  B R Herts; M E Baker
Journal:  Semin Urol Oncol       Date:  1995-11

4.  Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.

Authors:  John S Lam; Oleg Shvarts; Jonathan W Said; Allan J Pantuck; David B Seligson; Michael E Aldridge; Matthew H T Bui; Xueli Liu; Steve Horvath; Robert A Figlin; Arie S Belldegrun
Journal:  Cancer       Date:  2005-06-15       Impact factor: 6.860

5.  The correlation between size of renal cell carcinoma and its histopathological characteristics: a single center study of 1867 renal cell carcinoma cases.

Authors:  Cuijian Zhang; Xuesong Li; Han Hao; Wei Yu; Zhisong He; Liqun Zhou
Journal:  BJU Int       Date:  2012-04-30       Impact factor: 5.588

6.  Comparison of accuracy of 14-, 18- and 20-G needles in ex-vivo renal mass biopsy: a prospective, blinded study.

Authors:  Alberto Breda; Eric G Treat; Leah Haft-Candell; John T Leppert; Jonathan D Harper; Jonathan Said; Steven Raman; Robert B Smith; Arie S Belldegrun; Peter G Schulam
Journal:  BJU Int       Date:  2009-11-02       Impact factor: 5.588

7.  Fuhrman grade [corrected] has no added value in prediction of mortality after partial or [corrected] radical nephrectomy for chromophobe renal cell carcinoma patients.

Authors:  Malek Meskawi; Maxine Sun; Salima Ismail; Marco Bianchi; Jens Hansen; Zhe Tian; Nawar Hanna; Quoc-Dien Trinh; Markus Graefen; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz
Journal:  Mod Pathol       Date:  2013-02-01       Impact factor: 7.842

8.  A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis.

Authors:  Brett Delahunt; Jesse K McKenney; Christine M Lohse; Bradley C Leibovich; Robert Houston Thompson; Stephen A Boorjian; John C Cheville
Journal:  Am J Surg Pathol       Date:  2013-03       Impact factor: 6.394

9.  CT-guided biopsy for the diagnosis of renal tumors before treatment with percutaneous ablation.

Authors:  Marta E Heilbrun; Ronald J Zagoria; A Julian Garvin; M Craig Hall; Kyle Krehbiel; Andrew Southwick; Peter E Clark
Journal:  AJR Am J Roentgenol       Date:  2007-06       Impact factor: 3.959

10.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

View more
  16 in total

Review 1.  Review of renal cell carcinoma and its common subtypes in radiology.

Authors:  Gavin Low; Guan Huang; Winnie Fu; Zaahir Moloo; Safwat Girgis
Journal:  World J Radiol       Date:  2016-05-28

2.  Evaluation of renal cell carcinoma histological subtype and fuhrman grade using 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.

Authors:  Reiko Nakajima; Sayumi Nozaki; Tsunenori Kondo; Yoji Nagashima; Koichiro Abe; Shuji Sakai
Journal:  Eur Radiol       Date:  2017-05-18       Impact factor: 5.315

Review 3.  [Modern imaging of renal tumors - application in diagnostics and therapy. Characterization, operation planning and therapy monitoring of renal lesions].

Authors:  J P Radtke; D Teber; C D Alt; B A Hadaschik; P Hallscheidt
Journal:  Radiologe       Date:  2016-03       Impact factor: 0.635

4.  Statistical clustering of parametric maps from dynamic contrast enhanced MRI and an associated decision tree model for non-invasive tumour grading of T1b solid clear cell renal cell carcinoma.

Authors:  Yin Xi; Qing Yuan; Yue Zhang; Ananth J Madhuranthakam; Michael Fulkerson; Vitaly Margulis; James Brugarolas; Payal Kapur; Jeffrey A Cadeddu; Ivan Pedrosa
Journal:  Eur Radiol       Date:  2017-07-05       Impact factor: 5.315

5.  Usefulness of computed tomography textural analysis in renal cell carcinoma nuclear grading.

Authors:  Israa Alnazer; Omar Falou; Pascal Bourdon; Thierry Urruty; Rémy Guillevin; Mohamad Khalil; Ahmad Shahin; Christine Fernandez-Maloigne
Journal:  J Med Imaging (Bellingham)       Date:  2022-09-13

6.  Application of different methods used to measure the apparent diffusion coefficient of renal cell carcinoma on the same lesion and its correlation with ISUP nuclear grading.

Authors:  Gülhan Kılıçarslan; Yeşim Eroğlu; Ahmet Kılıçarslan
Journal:  Abdom Radiol (NY)       Date:  2022-05-16

Review 7.  [Noninvasive phenotyping of renal tumors-current state of the art].

Authors:  Hubert Stefan Bickel
Journal:  Radiologe       Date:  2018-10       Impact factor: 0.635

8.  Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma.

Authors:  Reiko Nakajima; Koichiro Abe; Tsunenori Kondo; Kazunari Tanabe; Shuji Sakai
Journal:  Eur Radiol       Date:  2015-09-24       Impact factor: 5.315

Review 9.  Identification of Tumor-Specific MRI Biomarkers Using Machine Learning (ML).

Authors:  Rima Hajjo; Dima A Sabbah; Sanaa K Bardaweel; Alexander Tropsha
Journal:  Diagnostics (Basel)       Date:  2021-04-21

Review 10.  DCE-MRI, DW-MRI, and MRS in Cancer: Challenges and Advantages of Implementing Qualitative and Quantitative Multi-parametric Imaging in the Clinic.

Authors:  Jessica M Winfield; Geoffrey S Payne; Alex Weller; Nandita M deSouza
Journal:  Top Magn Reson Imaging       Date:  2016-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.